Moeller 1986.

Methods	Four‐week, double‐blind study.
Participants	Female in‐patients with a Major Depressive Disorder (MDD) according to the DSM‐III criteria, and with a pretreatment score of at least 18 on the Hamilton Depression Rating Scale‐17 Item (HDRS‐17). Age range: 18‐65 years. Exclusion criteria: patients who did not give their informed consent, pregnant patients, patients with serious concomitant disease (heart, liver, kidney), patients with an organic cerebral syndrome, schizophrenics or patients with a paranoid psychosis, alcoholics or patients addicted to narcotics, patients with epilepsy, and patients having received MAO‐inhibitors within the last 3 weeks.
Interventions	Citalopram: 14 participants. Maprotiline: 13 participants. Citalopram dose range: 40‐60 mg/day. Maprotiline dose range: 75‐150 mg/day.
Outcomes	Primary outcome: plasma ratios of tryptophan (Trp) and Tyriosine (Tyr) to other large neutral amino acids.
Notes	This study was funded by Lundbeck (citalopram manufacturer). One patient in maprotiline group committed suicide.